Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

mTOR inhibitors in hematologic malignancies.

Janet E Dancey1

  • 1Investigational Drug Branch, Cancer Treatment Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 6130 Executive Boulevard, Rockville, MD 20854, USA. danceyj@ctep.nci.nih.gov

Clinical Advances in Hematology & Oncology : H&O
|November 1, 2005
PubMed
Summary

Rapamycin derivatives show promise for treating hematologic malignancies by inhibiting mammalian target of rapamycin (mTOR), a key regulator of cell growth. Clinical trials are evaluating these agents for improved cancer therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Outcome and Impact of Academic Cancer Clinical Trials with Participation from Canadian Sites (2015-2024).

Cancers·2025
Same author

Minding the gaps: assessing and addressing clinical research core competencies across a network of Canadian cancer centres.

Frontiers in pharmacology·2023
Same author

The Impact of COVID-19 on Academic Cancer Clinical Trials in Canada and the Initial Response from Cancer Centers.

Current oncology (Toronto, Ont.)·2022
Same author

CRAFT-A Proposed Framework for Decentralized Clinical Trials Participation in Canada.

Current oncology (Toronto, Ont.)·2021
Same author

Advancing Academic Cancer Clinical Trials Recruitment in Canada.

Current oncology (Toronto, Ont.)·2021
Same author

Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02.

Neuro-oncology advances·2020

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Hematologic malignancies often develop resistance to chemotherapy.
  • Rapamycin, an immunosuppressant, and its derivatives (RAD001, CCI-779) are being investigated as cancer therapeutics.
  • Rapamycin targets the mammalian target of rapamycin (mTOR) pathway, crucial for cell growth regulation.

Purpose of the Study:

  • To review advances in understanding rapamycin's cell growth inhibition mechanisms.
  • To summarize clinical trial results for RAD001 and CCI-779 in cancer treatment.
  • To explore the rationale for using rapamycin derivatives in hematologic malignancies.

Main Methods:

  • Literature review of rapamycin's mechanism of action.
  • Analysis of clinical trial data for RAD001 and CCI-779.

Related Experiment Videos

  • Examination of preclinical and clinical studies on rapamycin derivatives in hematologic cancers.

    • Main Results:

    • Rapamycin inhibits mTOR, affecting mRNA translation and cell cycle progression (G1 to S phase).
    • RAD001 and CCI-779 are under clinical development as anti-cancer agents.
    • The mTOR pathway is a relevant target for overcoming chemoresistance in hematologic malignancies.

    Conclusions:

    • Rapamycin derivatives offer a promising therapeutic strategy for hematologic malignancies.
    • Further investigation into mTOR inhibition is warranted for improving cancer treatment outcomes.
    • Understanding rapamycin's mechanism provides a basis for its application in oncology.